Baseline patient characteristics
| Characteristic . | MDACC (n = 165) . | IA/MC (n = 82) . | LY.12 (CCTG) (n = 219) . | CORAL (LYSARC) (n = 170) . | Pooled (N = 636) . |
|---|---|---|---|---|---|
| Median age, y (range) | 56 (20-81) | 60 (20-80) | 54 (24-70) | 54 (19-65) | 55 (19-81) |
| Male sex, % | 64 | 62 | 61 | 69 | 64 |
| Primary diagnosis, % | |||||
| DLBCL* | 76 | 89 | 84 | 100 | 87 |
| PMBCL | 1 | 0 | 5 | 0 | 2 |
| TFL | 3 | 0 | 10 | 0 | 4 |
| Indeterminate/missing | 19 | 11 | 1 | 0 | 7 |
| ECOG PS, % | |||||
| 0-1 | 42 | 72 | 89 | 84 | 73 |
| 2-4 | 10 | 24 | 11 | 15 | 14 |
| Missing | 49 | 4 | 0 | 1 | 13 |
| Disease stage, % | |||||
| I-II | 18 | 20 | 33 | 32 | 27 |
| III-IV | 82 | 79 | 67 | 67 | 72 |
| Missing | 0 | 1 | 0 | 1 | <1 |
| IPI risk classification, %† | |||||
| Low risk | 5 | 22 | 36 | 32 | 25 |
| Low-intermediate risk | 7 | 31 | 30 | 29 | 24 |
| High-intermediate to high risk | 23 | 48 | 35 | 34 | 33 |
| Missing or incompletely assessed | 65 | 0 | 0 | 5 | 18 |
| Refractory category, % | |||||
| Primary refractory | 0 | 24 | 51 | 28 | 28 |
| Refractory to ≥ second-line therapy | 90 | 51 | 21 | 46 | 50 |
| Relapsed ≤12 mo post-ASCT | 10 | 24 | 28 | 26 | 22 |
| Total no. of lines of chemotherapy and ASCT received, %‡ | |||||
| 1 | 0 | 24 | 51 | 28 | 28 |
| 2-3 | 90 | 50 | 21 | 46 | 49 |
| ≥4 | 0 | 1 | 0 | 0 | <1 |
| Characteristic . | MDACC (n = 165) . | IA/MC (n = 82) . | LY.12 (CCTG) (n = 219) . | CORAL (LYSARC) (n = 170) . | Pooled (N = 636) . |
|---|---|---|---|---|---|
| Median age, y (range) | 56 (20-81) | 60 (20-80) | 54 (24-70) | 54 (19-65) | 55 (19-81) |
| Male sex, % | 64 | 62 | 61 | 69 | 64 |
| Primary diagnosis, % | |||||
| DLBCL* | 76 | 89 | 84 | 100 | 87 |
| PMBCL | 1 | 0 | 5 | 0 | 2 |
| TFL | 3 | 0 | 10 | 0 | 4 |
| Indeterminate/missing | 19 | 11 | 1 | 0 | 7 |
| ECOG PS, % | |||||
| 0-1 | 42 | 72 | 89 | 84 | 73 |
| 2-4 | 10 | 24 | 11 | 15 | 14 |
| Missing | 49 | 4 | 0 | 1 | 13 |
| Disease stage, % | |||||
| I-II | 18 | 20 | 33 | 32 | 27 |
| III-IV | 82 | 79 | 67 | 67 | 72 |
| Missing | 0 | 1 | 0 | 1 | <1 |
| IPI risk classification, %† | |||||
| Low risk | 5 | 22 | 36 | 32 | 25 |
| Low-intermediate risk | 7 | 31 | 30 | 29 | 24 |
| High-intermediate to high risk | 23 | 48 | 35 | 34 | 33 |
| Missing or incompletely assessed | 65 | 0 | 0 | 5 | 18 |
| Refractory category, % | |||||
| Primary refractory | 0 | 24 | 51 | 28 | 28 |
| Refractory to ≥ second-line therapy | 90 | 51 | 21 | 46 | 50 |
| Relapsed ≤12 mo post-ASCT | 10 | 24 | 28 | 26 | 22 |
| Total no. of lines of chemotherapy and ASCT received, %‡ | |||||
| 1 | 0 | 24 | 51 | 28 | 28 |
| 2-3 | 90 | 50 | 21 | 46 | 49 |
| ≥4 | 0 | 1 | 0 | 0 | <1 |
CCTG, Canadian Cancer Trials Group; LYSARC, Lymphoma Academic Research Organization.
In the CORAL (LYSARC) study, the disease subtype for 96 patients was not available; per the study inclusion criteria, patients were to have DLBCL.
IPI was determined at diagnosis for MDACC and IA/MC and at randomization for LY.12 and CORAL study patients; low risk, 0-1 point; low-intermediate risk, 2 points; high-intermediate to high risk, ≥3 points.
Includes the 78% of patients who were refractory to chemotherapy and excludes those who relapsed post-ASCT.